Institutional investors purchased a net $567.5 thousand shares of IMGN during the quarter ended March 2018 and now own 79.76% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CAPITAL RESEARCH & MANAGEMENT CO... Bought 5.5 Million shares of ImmunoGen Inc
RENAISSANCE TECHNOLOGIES LLC Bought 3.7 Million shares of ImmunoGen Inc
POINTSTATE CAPITAL LP Bought 1.7 Million shares of ImmunoGen Inc